Pfizer's Third-Quarter Financial Performance
On a recent Tuesday, Pfizer Inc. (NYSE: PFE) reported third-quarter 2025 adjusted earnings of 87 cents per share, which is a decrease from $1.06 a year prior. However, this exceeded analysts' expectations, which had forecasted earnings of 63 cents.
Despite a challenging environment, Pfizer's third-quarter sales reached $16.65 billion. This represents a 6% decline year over year but still surpassed the anticipated figure of $16.59 billion. The operational decrease is attributed to a reduction in revenues from COVID-19 products, which has been largely affected by falling infection rates.
Impact of COVID-19 on Drug Sales
The drop in COVID-19 product revenues has had a noticeable impact on Pfizer's business, specifically on demand for Paxlovid and the vaccination rates for Comirnaty. The narrower vaccine recommendation has led to a smaller eligible population for vaccination.
Core Drug Performances
On a more positive note, Pfizer's core drugs have shown resilience. Sales from the Vyndaqel family, a heart medication, increased by 7%, reaching $1.59 billion. This growth is credited to heightened demand and increased patient diagnoses, especially in the U.S. and specific international markets where patient affordability has improved.
However, sales of the cancer treatment Ibrance fell by 5%, totaling $1.06 billion, reflecting challenges in the oncology market. In contrast, the blood thinner Eliquis saw revenue rise by a substantial 22% to around $2.02 billion, driven by greater demand globally, despite some price erosion internationally due to generic competition.
The sales for Comirnaty were reported at $1.15 billion, down 20%, primarily tied to the limited U.S. vaccination recommendations and delays in the approval of the updated variant vaccine. Furthermore, Paxlovid experienced a significant 55% decline in sales to $1.23 billion as COVID-19 infections continued to decrease.
Financial Outlook for 2025
Looking ahead, Pfizer has raised its adjusted earnings guidance for fiscal 2025, now projecting earnings of $3.00 to $3.15 per share. This is an adjustment from their previous forecast of $2.90 to $3.10 and aligns closely with the consensus estimate of $3.04. The company also reaffirms its sales guidance for 2025, forecasting revenues between $61 billion and $64 billion, slightly above the consensus of $62.88 billion.
Moreover, Pfizer’s revised guidance takes into account the effects of existing tariffs imposed by markets like China, Canada, and Mexico. The efficacy of the company's cost-control strategies has become evident as they navigate these challenges.
Current Stock Performance
PFE Price Action: At the time of reporting, Pfizer’s shares were down 1.05%, trading at $24.40. This decline reflects broader market movements and investor sentiments amidst mixed earnings signals.
Frequently Asked Questions
What were Pfizer's Q3 earnings for 2025?
Pfizer reported adjusted earnings of 87 cents per share for Q3 2025, a drop from $1.06 in the same quarter last year.
How did COVID-19 revenue affect Pfizer's overall sales?
COVID-19 product revenues significantly declined, contributing to a 6% drop in total sales year-over-year, even as overall sales reached $16.65 billion.
What is the outlook for Pfizer in 2025?
Pfizer has raised its adjusted earnings guidance to between $3.00 and $3.15 per share for fiscal 2025 and reaffirms its sales projections of $61 billion to $64 billion.
Which Pfizer drug saw the highest revenue growth?
The Vyndaqel family, a heart medication, saw a 7% increase in sales, reaching $1.59 billion due to growing demand and patient diagnoses.
What challenges did Pfizer's cancer treatment Ibrance face?
Ibrance experienced a 5% sales decline, totaling $1.06 billion, reflecting increasing competitive pressures in the oncology market.
